Recently, Novo Nordisk’s new indication application for a drug was accepted by the State Food and Drug Administration, which has aroused widespread concern. 　　As a multinational pharmaceutical giant, it is not uncommon for Novo Nordisk to apply for new indications for drugs. Why is there such a strong response this time? In the final analysis, it is still this drug named Ozempic or Wegovy-it is almost unknown in Europe and the United States, so that in China, many people have also heard of its “miraculous effect” on weight loss. 　　The main ingredient of this drug is “semaglutide”, which is currently suitable for the treatment of diabetes in China. In Europe…